



SmartPA Criteria Proposal

Drug/Drug Class:	Beta Adrenergic Blockers and Beta Adrenergic Blockers/Diuretic Combinations PDL Edit
First Implementation Date:	July 19, 2004
Revised Date:	January 12, 2023
Prepared for:	MO HealthNet
Prepared by:	MO HealthNet/Conduent
Criteria Status:	<input checked="" type="checkbox"/> Existing Criteria <input type="checkbox"/> Revision of Existing Criteria <input type="checkbox"/> New Criteria

Executive Summary

Purpose: The MO HealthNet Pharmacy Program will implement a state-specific preferred drug list.

Why Issue Selected: Beta-adrenergic blockers inhibit the chronotropic, inotropic and vasodilator responses to adrenaline by blocking β_1 and β_2 receptor sites throughout the body. Several characteristics of beta-blockers may be related to their clinical effectiveness. Beta blockers can be classified by cardioselectivity and intrinsic sympathomimetic activity (ISA). Cardioselective beta-blockers preferentially inhibit only β_1 receptors that are principally found in the myocardium while non-cardioselective beta blockers inhibit both β_1 and β_2 receptor sites. As a result of the being 20 times more potent at blocking β_1 vs β_2 receptors, the cardioselective agents are less likely to result in bronchoconstriction. Products with ISA are weak agonists of one or more β -adrenoceptor subtypes and were developed to reduce side effects and improve product tolerability.

Total program savings for the PDL classes will be regularly reviewed.

Program-specific information:

Preferred Agents	Non-Preferred Agents
<ul style="list-style-type: none"> • Acebutolol • Atenolol • Atenolol/Chlorthalidone • Bisoprolol • Bisoprolol/HCTZ • Carvedilol • Hemangeol[®] • Labetalol • Metoprolol Succinate • Metoprolol Tartrate • Metoprolol/HCTZ • Nadolol • Propranolol Soln/Tabs • Propranolol/HCTZ • Sorine[®] 	<ul style="list-style-type: none"> • Betapace[®] • Betapace AF[®] • Betaxolol • Bystolic[®] • Carvedilol ER • Coreg[®] • Coreg CR[®] • Corgard[®] • Inderal LA[®] • Inderal XL[®] • InnoPran XL[®] • Kaspargo[®] Sprinkle Caps • Lopressor[®] • Lopressor HCT[®] • Nadolol/Bendroflumethiazide

<ul style="list-style-type: none"> • Sotalol • Sotalol AF 	<ul style="list-style-type: none"> • Nebivolol • Pindolol • Propranolol LA • Sotylize® • Tenoretic® • Tenormin® • Timolol Maleate • Toprol XL® • Ziac®
---	---

Type of Criteria: Increased risk of ADE Preferred Drug List
 Appropriate Indications Clinical Edit

Data Sources: Only Administrative Databases Databases + Prescriber-Supplied

Setting & Population

- Drug/drug class for review: Beta Adrenergic Blockers and Beta Adrenergic Blockers/Diuretic Combinations
- Age range: All appropriate MO HealthNet participants

Approval Criteria

- Failure to achieve desired therapeutic outcomes with trial on 3 or more preferred agents
 - Documented trial period for preferred agents **OR**
 - Documented ADE/ADR to preferred agents
- For Bystolic: Adequate therapeutic trial on one vasodilating alpha/beta-adrenergic blocking agent (labetalol or carvedilol)
- For Coreg CR:
 - Documented diagnosis of heart failure **AND**
 - Adequate therapeutic trial on carvedilol twice daily for 30 days
- For Hemangeol:
 - Participants aged 2 years and younger **AND**
 - Documented diagnosis of infantile hemangioma **AND**
 - Maximum treatment length of 6 months; clinical consultant review required to extended treatment
- For Sotylize and Kaspargo Sprinkle: Clinical Consultant Review for participants aged 10 years or older

Denial Criteria

- Lack of adequate trial on required preferred agents
- Therapy will be denied if all approval criteria are not met

Required Documentation

Laboratory Results:
 MedWatch Form:

Progress Notes:
 Other:

Disposition of Edit

Denial: Exception Code "0160" (Preferred Drug List Edit)

Rule Type: PDL

Default Approval Period

1 year

References

- Evidence-Based Medicine Analysis: “Beta Adrenergic Blockers and Diuretic Combinations”, UMKC-DIC; July 2022.
- Evidence-Based Medicine and Fiscal Analysis: “Beta Adrenergic Blockers and Diuretic Combination Agents – Therapeutic Class Review”, Conduent Business Services, L.L.C., Richmond, VA; July 2021.
- USPDI, Micromedex; 2022.
- Facts and Comparisons eAnswers (online); 2022 Clinical Drug Information, LLC.